H.B. 30 Summary

• Creates a new chapter in Hawaii Revised Statutes to penalize prescription drug manufacturers for unsupported price increases on drugs sold in the state.

• Applies to manufacturers with at least $250,000 in annual drug sales in Hawaii; penalties equal 80% of revenue excess above inflation-adjusted prior year wholesale acquisition cost.

• Relies on Institute for Clinical and Economic Review's annual Unsupported Price Increase Report to identify affected drugs; manufacturers receive 60-day notice and face 2-year penalty period per identified drug.

• Prohibits manufacturers from withdrawing identified drugs from the state to avoid penalties; requires 180-day withdrawal notice and imposes $500,000 penalty for violation.

• Establishes the Identified Drug Offset Special Fund to collect penalties and use revenues to offset consumer out-of-pocket costs for identified drugs, with optional administrative cost coverage; requires annual legislative reports.